Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography

Annals of Surgery

Volumn 233, Issue 3, 2001, Pages 300-309

  Brucher, Bjorn L D M ^a,b   Weber, Wolfgang ^a   Bauer, Markus ^a   Fink, Ullrich ^a   Avril, Norbert ^a   Stein, Hubert J ^a   Werner, Martin ^a   Zimmerman, Frank ^a   Siewert, J Rudiger ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; CANCER CELL DESTRUCTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIAGNOSTIC IMAGING; DRUG INFUSION; DRUG RESPONSE; ECHOGRAPHY; ENDOSCOPY; ESOPHAGUS CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MALE; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0035112099     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200103000-00002     Document Type: Article

References (38)

1. Multimodal therapy of tumors of the upper gastrointestinal tract
2. Current strategy in surgery for esophageal cancer
3. Neoadjuvant therapy for squamous cell esophageal carcinoma
4. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma
5. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trial
6. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer
7. Response to chemotherapy in esophageal cancer
8. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation
9. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy
10. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy
11. Chemotherapy in oesophageal cancer
12. Relevance of positron emission tomography (PET) in oncology
13. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose
14. Improvement in staging of esophageal cancer with the addition of positron emission tomography
15. 18F-fluorodeoxyglucose positron emission tomography
16. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy
17. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma
18. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
19. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
20. Preoperative risk analysis and post-operative mortality of oesophagectomy for resectable oesophageal cancer
21. Risk analysis in esophageal surgery
22. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus
23. Multimodal treatment for squamous cell esophageal cancer
24. Esophagus carcinoma-systemic or local risk of recurrence-which perioperative measures are successful?
25. Reporting results of cancer treatment
26. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
27. The applications of PET in clinical oncology
28. Surgery for carcinoma of the esophagus
29. En-bloc esophagectomy in esophageal cancer
30. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations
31. Nonparametric estimation from incomplete observations
32. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
33. Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with fluorodeoxyglucose
34. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
35. FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors
36. Reproducibility of metabolic measurements in malignant tumors using FDG PET